Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-24 DOI:10.1080/14796694.2025.2527477

Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger

{"title":"Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.","authors":"Mehmet Ali Nahit Sendur, Nuri Karadurmus, Irfan Cicin, Mahmut Gumus, Umut Demirci, Ozgur Ozyilkan, Muhammet Ali Kaplan, Sema Sezgin Goksu, Feyyaz Ozdemir, Cagatay Arslan, Basak Oyan Uluc, Erdem Goker, Muhammed Mustafa Oksuzokyar, Yasemin Esen, Mert Batum, Milan van Rheenan, Bernadette Poellinger","doi":"10.1080/14796694.2025.2527477","DOIUrl":null,"url":null,"abstract":"Background: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye.Research design and methods: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.Results: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.Conclusions: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2525-2535"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330250/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2527477","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye.

Research design and methods: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.

Results: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.

Conclusions: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.

查看原文本刊更多论文

评估土耳其转移性非小细胞肺癌患者一线治疗中不断发展的实践模式的实施情况（ESTIMATE）：一项全国性、多中心、回顾性、真实世界证据研究。

背景：这是一项全国性、多中心、回顾性、非介入性的真实世界证据研究，旨在解决 rkiye转移性非小细胞肺癌（mNSCLC）患者的患者特征和系统治疗实践。研究设计和方法：在6个月的时间里，土耳其12个肿瘤中心的636名成年小细胞肺癌患者提供了回顾性数据。结果：腺癌是最常见的组织学，95%有远处骨转移，64.8%无合并症。最常用的一线治疗是联合化疗，然后是靶向治疗和免疫治疗。总体而言，55.5-69.3%的患者进行了ALK、EGFR、ROS1和PD-L1检测。结论：与其他国家相比，日本对小细胞肺癌患者的生物标志物筛查并不理想，尤其是在公立医院。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.